<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 176 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page175.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=176">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 176 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 176</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=176"><img src="../thumb/176.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Blood and Haemopoeitic - 8.4 / 8.5 / 8.6                                       2020-04 / 143
       unt.less than 6 mnths), MI (from a few days unt. &lt;35 days) or est.   ZYKLOT 75, Zydus [P/S]  (S4) SOL FOR INJ, 41/8.3/0886; 0887; 0888; 0889; 0890; 0891; 0892; 0893
       periph.arter.dis.             Clopidogrel                  714018-001: 20 µg/0,5 ml, sngl.pre-fill.syr., R391,15
       (S3) TABS, 40/8.2/0673        Indications: Reduct.of atherothrombot.events as follows:  714019-001: 30 µg/0,3 ml, sngl.pre-fill.syr., R586,72
       711423-001: 75 mg, 30, R97,79  Rec.MI/stroke/est.periph.arter.dis: Reduct.of atherothrombot.  715971-001: 40 µg/0,4 ml, sngl.pre-fill.syr., R782,29
       Dosage: 75 mg as sngl.dly.dos.  events (MI/stroke/death due to vasc.causes).in pts. with hist.of symp-  715973-001: 50 µg/0,5 ml, sngl.pre-fill.syr., R977,87
       Contraindications: Act.bleed., safety & effic.in pts. bel.18 yrs./  tomat. atherosclerot. dis.defin.by ischaem.stroke from 7 days until   714020-001: 60 µg/0,3 ml, sngl.pre-fill.syr., R1 173,44
       pregn.& lactat.not est., sev.liv. impairm., thrombocytopen., platel.  &lt;6 mnths, MI from a few days until &lt;35 days or est.periph.arter.dis.  715974-001: 80 µg/0,4 ml, sngl.pre-fill.syr., R1 564,55
       dysfunct., safety of chron.concom.acetylsalicyl.acid admin.not est.,   Ac.coron.syndr: In combin.with ASA decr.rate of a combin. end-  715975-001: 100 µg/0,5 ml, sngl.pre-fill.syr., R1 955,70
       safety with concom.heparin/other thrombolytic./ warfar. not est.  point of CV death/MI/stroke or refract. ischaem.for pts.with non-ST   714021-001: 150 µg/0,3 ml, sngl.pre-fill.syr., R2 933,54
       Side-effects: Purpura, bruis., epistax., IC /GI haemorrh., sev.neutro-  segm.elev. ac.coron.syndr.(unstab.angina/non-Q-wave MI) incl.pts.  Dosage: Do not mix with other products. Admin. either SC/IV to
       pen./thrombocytopen., haematur., ocul./resp.tract/musculoskelet.  to be manag.medic./with percutan. coron.intervent.with/without   incr.Hb to not great.than 12 g/dl. SC use pref.when not receiv.hae-
       bleed., aplast. anaem., pancytopen., haemorrh.ulc., haemothorax,   stent or CABG, in combin. with ASA reduc. death rate from any   modialys. Intra pt. Hb.value variabil.observ. which should be address.
       operat.wound & retroperiton. haemorrh., hypersens.reacts.incl. bron-  cause & rate of combin. endpoint of death/re-infarct./stroke in pts.  through dose managem.with Hb target range 10-12 g/dl. Sust.lev.of
       chosp./ angioed./anaphylact.reacts., CNS effs., dizzin., headache, par-  with ST-segm.elev.ac.MI  12 g/dl should be avoid. Decr. dos.if Hb rise exceed 1 g/dl in any 2
       aesthes., IC bleed., vertigo, taste disords., chest/back/gen.pain, atrial   (S3) TABS, 46/8.2/0972  wk.period. Treatm. div.into two stages namely correct.& maint. phase.
       fibrillat., palpitat., oed., hyper-/hypotens., vasculit., URTI, bronchit.,   300177-001: 75 mg, 30, R176,40  Correct.phase: Init.0,45 µg/kg body weight SC/IV as sngl.inj.once
       dyspn., cough, rhinit., interstit. pneumonit., GI disturbs., tooth disords.,   Dosage: Rec.MI/stroke/est.periph.arter.dis: 75 mg once dly.  wkly. Alternativ.pts.not on dialys. init.0,75 µg/kg SC as sngl.inj.once
       abnorm. LFTs, hepatit., ac.liv.fail., skin reacts.incl.erythema multiforme   Ac.coron.syndr: Pts.with non-ST-segm.elevat. ac. coron.syndr.(un-  every 2 wks. If Hb incr.inadeq.(ie.less than 1 g/dl in 4 wks.) incr. dos.
       /Stev.-John. syndr. & tox.epiderm. necrolys./lichen planus, arthralg.,   stable angina/non-Q-wave MI): Init.with sngl. 300 mg load.dos.&   by approx.25 %. Dos.incr.not more freq.than once every 4 wks. If Hb
       gout, leg cramps, myalg., arthrit., UTI, glomerulonephrit., incr.creatin.  cont.at 75 mg once dly. Aspir.75-325 mg once dly.to be giv. in com-  incr.more than 1 g/dl in a 2 wk.period decr.dos.by 25 %. If Hb con-
       lev., flu-like sympt., fatig., asthen.  bin. Pts.with ST-segm.elevat. ac.MI: Recomm. dos.is 75 mg once   tin.to rise aft. dos.reduct.withold.dos.until Hb begins to decr.& then
       Warnings and special precautions: Warn. pts.of TTP S&S, dis-  dly admin.in combin.with aspir. with/without thrombolyt. May be   re-init.at approx.25 % low.than prev.dos. Meas.Hb every 1-2 wks.till
       cont.ther.if TTP susp., dent.& surg.proced., incr.act.bleed.risk, concom.  init.with/without a load.dos.  stable and thereaft.at long.interv.
       meds. incr.bleed.risk eg. anticoags./NSAID’s incl.COX-2 inhibits./  Contraindications: Risk of act. bleed.incl. pept.ulc./ IC haemorrh.,   Maint.phase: Cont.ther.as once wkly or once every two wks.sngl.inj.
       glycoprot. IIb & IIIa inhibit., concom.aspir. in rec.TIA/stroke, first few   safety & effic.in childr.&lt;18 yrs/pregn. & lactat.not est., sev.liv.impairm.,   Dialys.pts.convert.from once wkly to once every other wk.dos.admin.
       days aft.MI, not recomm. in CABG & ac.ischaem.stroke ie.less than   thrombocytopen., platel.dysfunct.  init. dos.equiv.to twice the prev.once wkly dos. In pts. not on dialys.
       7 days, pts.to be aware that bleed.may take long. than usual to stop   Side effects: Thrombot.thrombocytopen.purpura (TTP), bleed.time   who achiev.targ.Hb wih once every 2 wk.dos.admin.dos.SC once
       & report unusual bleed.& advise other medic.practit.accord., monit.  prolong., bld.dyscras., anaem., neutropen. somet.sev., GI/IC/eye/  mnthly using init.dos. equal to twice prev.once every 2 wk.dos. Titrat.
       for bleed.signs incl. occult bleed.esp.dur.first ther.wks.&/ aft. invas.   nose/skin/ musculoskelet./ resp.tract bleed.& at arter.punct. sites,,   to maint.Hb target. If adjustm.necess.adjust dos.by approxim.25 %. If
       card.surg./proced., discont.7 days prior to elect. surg.if antiplatel. eff.  gynecomast., general.pain, flu-like sympts., syncope, asthen., fatig.,   Hb incr.more than 1 g/dl in a 2 wk. period decr.dos.by approx.25 %. If
       not desir., pts.with les. with propensity to bleed/concom.meds.which   fev., headache, dizzin., paraesthes., vertigo, haematoma, GI disturbs.,   Hb exceeds 12 g/dl discont.until Hb falls bel.12 g/dl & then re-init.at
       poss. induc.les., ren.impairm., mod.hepat.dis.  atrial fibrillat./ palpitat.,oed., hypertens., chest pain, URTI, bruis.,   approx.25 % low.than prev.dos. Dos. changes not to be made more
       Drug interactions: Eff.of acetylsalic.acid on collag. induc.plate-  freq.than every 2 wks. When change route of admin.use same dos.
       let aggregat.potent., incr.bleed. risk with heparin, incr.bleed.intens.  skin reacts.incl.erythema multiforme /Stev.John.syndr./tox.epiderm.   & monit.Hb every 1-2 wks.
                                     necrolys./ lichen planus, haematur., UTI, operat. wound haemorrh.,
       with warfarin, poss. incr.lev.of drugs metabol.by CYP2C9 enzyme.  Convert.from 1/2/3x wkly r-HuEPO: Determ. init. wkly Aranesp
                                     bleed.with fatal outcome, retroperiton. haemorrh., anaphylact.reacts,   dos by div.tot.wkly r-HuEPO (iu/wk) dos.by 200. Init.every other wk
       PLAVIX, Sanofi-Aventis [P/S]  ser. sickn., CNS effs., Kounis syndr., hallucin., taste disords., vascu-  Aranesp. dos.determ.by div.tot.cumulat.r-HuEPO dos over 2 wk.period
       Clopidogrel                   lit., hypotens., bronchosp., bronchit., dyspn., cough, arthrit., interstit.  by 200. When substit.Aranesp for r-HuEPO monit.Hb every 1-2 wks.&
       Indications: Reduct.of atherosclerot.events in pts. with hist.of symp-  pneumonit., colit., pancreatit., stomatit., abnorm.liv.funct.tests, hep-  use same route of admin.
       tomat.atherosclerot.dis. defin.by ischaem. stroke from 7 days until &lt;6   atit., ac.liv.fail., arthrit., arthralg., myalg., gout, back pain, leg cramps,   Contraindications: r-HuEPO hypersens., uncontrol. hypertens.,
       mnths, MI from a few days until &lt;35 days or est.periph.arter. dis.  glomerulonephrit., incr.bld. creatin.  safety in pregn.& lactat.not est.
       (S3) TABS, 36/8.2/0408        Warnings and special precautions: Pts.to be advis. of TTP S&S,   Side effects: Pure red cell aplas.caus.by neutralis. anti-erythropoiet.
       874965-004: 75 mg, 28, R714,89  eval.pt for hist.of hypersens.to thienopyridines, acquir.haemophil.,   antibod.report. predomin. in CRF treat.SC., convuls., elev.ser.K  lev.,
                                                                                            +
       Dosage: 75 mg as sngl.dly.dos.  not recomm.in ac. ischaem.stroke (less than 7 days), spin./epidur.   ser.allerg.reacts.incl.dyspn., hypertens., vasc. access thrombos., SC
       Contraindications: Act.patholog.bleed., sev. liv. impairm., safety &   anaesthet./lumb.punct.dur.treatm./7 days thereaft., discont.7 days   inj site discomf., thromboembol. events, rash, erythema.
       effic.in childr.&lt;18 yrs/pregn.& lactat.not est.  prior to elect.surg.if antiplatel. eff.not desir, concom.ASA/heparin   Special precautions: Monit.BP imperative esp. dur.init., eval. Fe
       Side effects: Haemorrhag.disords., bld.dyscras., thrombot. throm-  /thrombolyt. agents/NSAIDs incl.COX-2 inhibits./ glycoprot.IIb/IIIa   status prior to & dur.ther.& supplem. Fe ther.recomm.in all pts.with
       bocytopen.purpura(TTP), GI disturbs., skin rash, prurit., CNS effs.,   inhibit., incr.bleed.risk with warfar., concom.strong/mod.CYP2C19 in-  ser. ferritin values bel.100 µg/L or transferr.saturat. bel. 20 %, inves-
       hepat.& bil. disords., hypersens.reacts.  hib. (eg.omeprazole & esomeprazole) not recomm., concom.CYP2C8   tig.causat.fact.if non-respons.to ther., Fe/folic acid or Vit.B defic may
       Special precautions: Pts.at risk of incr.bleed., discont. 7 days pri-  substrates, pts. to be aware that bleed. may take long.than usual to   reduc. effectiven., intercurr.infects./inflamm.or traumat. episod./ oc-
       or to surg.if antiplatel.eff.not desir., meds.(eg.acetylsalicylic acid &   stop & to advise other medic.practit.accord., pts.at incr.risk of bleed.   cult bld.loss/haemolys./sev.Al toxic./ underly. haematolog.dis./bone
       NSAID’s) that may induc.les.with propens.to bleed, pts.to be aware   from les.with propens to bleed esp.GI & intra-ocul./trauma/surg.or   marr.fibros.may comprom. erythropoiet.respons., consid.bone marr.
       that bleed.may take long.than usual to stop & to advise other medic.  other patholog.condits., caref. monit.for bleed.esp.but not limit.to   exam. if reticulocytopen.pres., test for anti-erythropoiet. antibod.if
       practit.accord., mod. hepat. dis., not recomm.in unstable ang./PTCA   dur.1  wk. of treatm.&/aft.card.proced./surg., mod.hepat. dis., ren.  bone marr.consist.with pure red cell aplas. (PRCA), neutralis.anti-
                                       st
       (stent) /CABG, ren.impairm., concom.warfarin not recomm., concom.  impairm., cons.bld.cell count &/other appropr. test.in case of clinic.  erythropoietin antibod.shown to cross react with erythropoietic prot.
       ASA, heparin & thrombolyt.    bleed.sympt.dur.ther         theref.if neutralis.antibod. suspect./ confirm.do not treat with Aranesp
       Drug interactions: Warfarin incr.bleed.intensity, eff.of acetylsalic.  Interactions: Poss.pharmacodynam.interact. betw. clopidogrel   or discont. ther., safety & effic.not est.in imp.liv. funct. /epilep./sickle
       acid on collag.induc.platelet aggregat. potent., poss.incr.lev.of drugs   & glycoprot.IIb/IIIa inhibit./ASA/ heparin, reduc.eff.with concom.  cell anaem., life-threaten.CV syst. complicat.assoc.with misuse by
       metabol. by CYP2C9 enzyme.    meds.inhib. CYP2C19 activ., act.of one of the Cytochrome P 450 (CYP)   healthy persons, do not exceed upper limit.of recom.target maint. Hb
       SPEC CLOPIDOGREL, (Activo) Specpharm [P/S]  enzym.(CYP 2C9)poss.inhib., poss.incr. plasma lev.of phenytoin/tol-  conc.in chron.ren.fail., incr.death risk & ser. CV events & vasc.access
       Clopidogrel                   butamide/tamoxifen/ fluvastatin/NSAID metabol.by CYP 2C9, eff.of   thrombos.observ.if admin. to target Hb great.than 12 g/dl, poss.allerg.
       Indications: Reduct.of atherosclerot.events in pts. with hist.of symp-  acetylsalic.acid on collag.induc.platelet aggregat. potent, incr.bleed.  reacts. from needle cover which contains dry nat. rubber, monit.ser.
                                                                   +
       tomat.atherosclerot.dis. defin. by ischaem.stroke from 7 days until.&lt;6   risk with concom.SSRIs.  K  lev., interact.poss.with high. bound RBC meds.eg.cyclospor/tac-
       mnths, MI from a few days until &lt;35 days or est. periph. arter.dis.  rolimus theref. monit. if admin.concom.
       (S3) TABS, 43/8.2/0725                                     See also MDR page 140.
       719884-001: 75 mg, 30, R206,41  8.5   Sclerosing agents    AUTRIN, (Aspen Pharmacare) Pharmacare [P/S]
       Dosage: 75 mg as sngl.dly.dos.                             Vit.B12 15 µg with intrins.fact.conc. (1½ NFU), Fe-fumarate 350 mg
       Contraindications: Act.bleed., safety & effic.in childr.&lt;18 yrs./     No products listed  (115 mg Fe), Vit.C 150 mg, folic acid 2 mg.
       pregn.& lactat.not est., sev.liv. impairm., thrombocytopen., platel.  Indications: Common anaem.
       dysfunct., safety in chron. concom.acetylsalicyl.acid not est., concom.   (S1) CAPS. H689.
       warfarin, safety with concom.heparin/ other thrombolytic.not est.  8.6  Haematinics  705853-004: 30, R146,81
       Side effects: Thrombot.thrombocytopen.purpura (TTP), agranulocy-  Dosage: 1 cap dly with/aft.meals.
       tos., granulocytopen., incr.bleed. time, decr.platelets, purpura, bruis.,      (See also 20.3)  Contraindications: Iron intol., with repeat. bld.transfus., ser.folic
       epistax., haematur., ocul./resp.tract/musculoskelet./IC bleed., sev.  ARANESP (MDR Listing)  acid defic./anaem.not produc.by Fe defic.unless Fe defic.present.
       neutropen., leukopen., decr.neutroph., eosinoph., aplast.anaem., pan-  COSMOFER (MDR Listing)  Side effects: GI effs., darken./black stools, haematemes., circulat.
       cytopen., sev. thrombocytopen., haemorrh.ulc., haemothorax, operat.   EPREX (MDR Listing)  fail.in sev.cas., later: metab.acidos., convuls., coma, liv.necros.&
       wound & retroperiton. haemorrh., GI disturbs., skin reacts.incl.ery-  FERINJECT (MDR Listing)  hepat.coma.
       thema multiforme /Stev.-John.syndr.& tox.epiderm.necrolys./lichen   Special precautions: Period.examinat./bld. studies recomm.in
       planus, paraesthes., headache, dizzin., vertigo, syncope, CNS/psych.   MONOFER (MDR Listing)  pernic.anaem., folic acid may obscure pernic.anaem., poss.toxic.in
                                     NPLATE (MDR Listing)
       effs., taste disords., vasculit., hypotens., hepatit., ac.liv.fail., glomeru-  childr.with excess.dos., poss.Fe overload.& toxic.in pts. receiv.oral &
       lonephrit, fev., arthralg., arthrit., myalg., anaphylax., ser. sickn., bron-  REVOLADE (MDR Listing)  parent.admin., Fe storage/absorpt. dis., haemoglobinopath., exist.GI
                                     VENOFER (MDR Listing)
       chosp./interstit.pneumonit., angioed., abnorm. LFT, incr.bld.creatin.  dis., observe 2 hrs.interv.betw.concom.quinolones.
       Warnings and special precautions: Warn. pts.of TTP S&S, dis-  ABIC LEUCOVORIN, (Cipla Medpro) Teva [P/S]  Drug interactions: Fe salt & tetracycl.absorpt. decr.if taken con-
       cont.ther.if TTP susp., dent.& surg.proced., incr.act.bleed.risk, concom.  Leucovorin Ca pentahydr.equiv.to leucovorin.  com., antacids & tea decr. absorpt., reduc.eff.of penicillamine, qui-
       meds. incr. bleed.risk eg.anticoags./NSAID’s incl.COX-2 inhibits./  Indications: Calcium leucovorin rescue. Ameliorat.of the bld.picture   nolone absorpt.decr.
       heparin/ASA/glycoprot.IIb & IIIa inhibit., monit. for bleed.signs incl.  in a number of megaloblast.anaemias due to folate defic.
       occult bleed.esp.dur. first ther.wks.&/aft.invas.card.surg./proced.,   (S1) SOL.FOR INJ. 27/8.3/0151, 0152, 0153. 10 mg/ ml.  COSMOFER, Litha [P/S] &
       discont. 7 days prior to elect.surg.if antiplatel. eff. not desir., ren.im-  704608-001: 1x10 ml, 100 mg/10 ml, R243,05  Iron(III)-hydroxide dextran complex equiv.to Fe.
       pairm., mod.hepat.dis., first few days aft.MI, not recomm.in CABG   704609-001: 1x20 ml, 200 mg/20 ml, R486,15  Indications: Sev.Fe defic.in adult pts.intol./not respond. to oral
       & ac.ischaem. stroke ie.less than 7 days, concom.aspir.in rec. TIA/  704610-001: 1x30 ml, 300 mg/30 ml, R729,17  Fe.when confirm.by appropr. investigat.
       stroke, pts.to be aware that bleed.may take long.t han usual to stop   For further details refer to manufac.prod.lit.  (S3) INJ, 37/8.3/0434. 50 mg/ml
       & report unusual bleed.& advise other medic.practit.accord., pts.with   711596-002: 5x2 ml amps, R764,93
       les. with propensity to bleed/concom.meds.which poss. induce les.  ARANESP, Amgen &  713080-001: 2x10 ml amps, R1 529,86
       Drug interactions: Eff.of acetylsalic.acid on collag. induc.platelet   Darbepoetin alfa  Dosage: IV admin.only by slow IV inj./IV drip infus./ into venous limb
       aggregat.potent., incr. bleed. risk with heparin/warfar./NSAIDs, poss.  Indications: Anaem.assoc.with chron.ren.fail.in adults & paed.  of dialyser dur. haemodialys. IV drip infus.pref.route. May be admin.
       incr.lev.of drugs metabol.by CYP2C9 enzyme.  pts.&gt;11 yrs.  undil.IM. Do not mix with other meds for simultan. admin. 0,9%</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page175.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page171.html">171</a>&nbsp;&nbsp;&nbsp;<a href="page172.html">172</a>&nbsp;&nbsp;&nbsp;<a href="page173.html">173</a>&nbsp;&nbsp;&nbsp;<a href="page174.html">174</a>&nbsp;&nbsp;&nbsp;<a href="page175.html">175</a>&nbsp;&nbsp;&nbsp;<a href="page176.html">176</a>&nbsp;&nbsp;&nbsp;<a href="page177.html">177</a>&nbsp;&nbsp;&nbsp;<a href="page178.html">178</a>&nbsp;&nbsp;&nbsp;<a href="page179.html">179</a>&nbsp;&nbsp;&nbsp;<a href="page180.html">180</a>&nbsp;&nbsp;&nbsp;<a href="page181.html">181</a>
             </td>
             <td width="35%"><a href="page177.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page177.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
